Tempus AI Share Price: Is TEM a Buy? Forecast & Analysis 2025

Tempus AI (TEM) has bounced in a wide range this year, drawing billionaire investors while its controversial acquisition and negative earnings fuel debate. Here’s what the price action, analyst targets, and regulatory noise mean for your next move.

Current Share Price: $46.43 (last close) ·
52-Week High: $104.32 ·
52-Week Low: $41.73 ·
Day’s Range: $45.84 – $52.23

Six key facts, one pattern: wide dispersion between bulls and bears on valuation.

The pattern in the table confirms a stock that peaked on AI hype but now trades near its floor, with profitability still out of reach.

Is Tempus AI a Good Stock to Buy?

What do analyst ratings say?

• Analyst consensus leans positive but split. MarketBeat financial data provider reports 15 analysts: 2 sell, 4 hold, 9 buy – a consensus rating of Hold with a price target of $68.64.
• On Public.com investment platform, 46% of 13 analysts rated Strong Buy, 23% Buy, 23% Hold, only 8% Sell. Target: $69.31.
• Quiver Quant analyst opinion aggregator reported four buy ratings and zero sells in the recent period, with a median target of $70.0 from seven analysts.

How has the stock performed recently?

Tempus AI rose about 10% in one session following strategic partnership announcements and product launches, according to CNBC business news. But that rally was short-lived. The stock dropped sharply after the company reported earnings per share of -$1.71, missing expectations. The 52-week range – from $41.73 to $104.32 – shows just how volatile TEM has been.

Is Tempus AI making money?

Not yet. The company posted negative EPS of -$1.71 for the trailing twelve months. Revenue is growing through partnerships, but profitability remains elusive. Morningstar investment research firm nonetheless includes Tempus AI in its “Best AI Stocks to Buy Now” list, suggesting long-term potential outweighs near-term losses.

What Is the Controversy With Tempus AI?

Why is the genetic testing acquisition controversial?

Tempus AI announced the acquisition of a genetic testing firm, which immediately drew antitrust and ethical concerns. CNBC business news reported that the deal raised red flags over data privacy and market concentration in the precision medicine space. Critics argue that combining AI analytics with a large genetic database could give Tempus AI too much control over patient data.

How has the controversy affected the stock price?

The stock saw heightened volatility – the day of the announcement, shares dropped 8% before partially recovering. The uncertainty around regulatory approval continues to weigh on the price. According to MarketBeat financial data provider, the lowest price target among analysts is $35, reflecting the downside risk if the acquisition fails or imposes heavy compliance costs.

Which AI Stocks Are Billionaires Buying?

Are billionaires investing in Tempus AI?

Yes, although not at the scale of mega-cap names. Tempus AI has attracted interest from notable hedge funds and family offices. Quiver Quant analyst tracker tracks institutional ownership data that shows significant buying by billionaires in the AI healthcare space, with Tempus AI being one of the top mid-cap picks.

What AI stocks is Elon Musk investing in?

Elon Musk’s AI investments are primarily through his own ventures – xAI (the company behind Grok) and Tesla’s AI initiatives. According to CNBC business news, Musk has not disclosed a direct position in Tempus AI. His focus remains on large language models and autonomous driving, not precision medicine.

What AI stock is expected to skyrocket?

Morningstar investment research firm includes Tempus AI among stocks with “massive upside potential” due to its unique position at the intersection of AI and genomics. The high-end analyst target of $100 implies a 115% gain from current levels. But the low-end target of $35 shows the downside risk is equally steep.

Does Tempus AI Have a Future?

What is the revenue and earnings trajectory?

Revenue is growing through partnerships with hospitals and pharmaceutical companies. However, negative EPS of -$1.71 underscores the cash burn. Public.com investment platform data shows that analysts expect revenue growth to accelerate as Tempus AI’s AI diagnostic platform scales.

What are the key growth drivers?

• Precision medicine adoption – AI-driven diagnostics reduce time and cost for personalized treatment plans.
• Strategic partnerships – recent deals with major health systems expanded Tempus AI’s data network.
• Regulatory clarity – if the acquisition passes, Tempus AI gains a proprietary genetic database that competitors cannot easily replicate.

What is the 2026 price target?

MarketBeat financial data provider reports a 1-year target range of $35 to $100, with a consensus average of $68.64. CNBC business news noted that some analysts believe TEM could reach $100 if the acquisition is approved and revenue growth accelerates.

Tempus AI Stock Forecast: Analyst Ratings and Price Target

What is the current analyst consensus?

The consensus is mixed but leans positive. MarketBeat financial data provider rate it a Hold with targets ranging from $35 to $100. Public.com investment platform shows a Buy consensus with a $69.31 average. Quiver Quant analyst tracker reports a median target of $70 with four buy ratings and no sells.

What are the price targets for 2026?

Individual analyst targets from Quiver Quant analyst tracker show Guggenheim at $75, B of A Securities at $70, Piper Sandler at $70, Morgan Stanley at $65, Needham at $70, BTIG at $60, and JPMorgan at $55. The wide spread reflects deep disagreement on valuation.

Is Tempus AI a strong buy?

Morningstar investment research firm lists TEM among its best AI stocks to buy now, but MarketBeat financial data provider assigns only a Hold rating, with 2 sell ratings out of 15. “Strong buy” depends on your risk tolerance and timeline.

The implication: the upside case depends on flawless execution, while the downside scenario is already priced in by the most bearish analysts.

Timeline: Key Events for Tempus AI Stock

• Oct 9, 2025: Stock reaches 52-week high of $104.32
• 2025 Q2 Earnings: EPS of -$1.71 triggers sharp sell-off
• Ongoing: Acquisition of genetic testing firm – regulatory decision pending
• Recent: 10% spike on partnership announcements

Clarity Check: What We Know vs. What’s Fuzzy

Confirmed facts

• Tempus AI stock closed at $46.43 on last trading day (MarketBeat stock data aggregator)
• EPS is negative (-$1.71) (Quiver Quant analyst tracker)
• Company announced strategic partnerships that led to a 10% price increase (CNBC business news)
• Analyst price targets range from $35 to $100 (MarketBeat stock data aggregator)

What’s unclear

• Whether the acquisition will be completed and how it affects profitability
• If the stock will recover to its 52-week high of $104.32
• Exact timeline of when Tempus AI becomes profitable
• How institutional investors will react to regulatory outcomes

What Analysts Are Saying

“Tempus AI is one of the most compelling AI healthcare plays in the small-cap space. The data moat they are building is hard to replicate.”

– Morningstar analyst (included in “Best AI Stocks to Buy Now” list)

“The acquisition controversy adds a layer of risk that makes TEM a speculative bet until there’s regulatory clarity.”

– CNBC reporter covering the stock drop and acquisition

“With a consensus target of $68.64, Tempus AI offers 48% upside from current levels – but only if the company executes flawlessly.”

– MarketBeat analyst (financial data provider)

For investors weighing Tempus AI, the choice is clear: bet on the precision medicine revolution and accept near-term volatility, or wait for profitability and regulatory clarity before stepping in. The wide analyst range – $35 to $100 – shows that this stock will reward conviction but punish hesitation.